ClinicalTrials.gg
WithdrawnNCT06935474Updated Jul 16, 2026

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

A Phase 1/2 interventional study of C-CAR168 in Lupus Nephritis (LN), sponsored by AbelZeta Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by AbelZeta Inc. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision to discontinue development and pursue an alternative clinical development strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
91st of 100
0 · median 50
Started
2026
with 14 others
Phase 1/2
12 of 114
6 open now
Registered
96th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 91st largest by enrollment of the 100 interventional ones that give a count, is one of 15 that started in 2026, is one of 12 in phase 1/2, and was the 96th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

This multi-center, open-label, Phase 1/2 study aims to evaluate the safety, tolerability, and preliminary efficacy of C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy, in patients with autoimmune diseases refractory to standard treatments. The study includes both dose escalation and dose expansion phases, with participants grouped into condition-specific cohorts.

The purpose of this study is to:

  1. Test the safety and ability for subjects with autoimmune refractory to standard treatment to tolerate the C-CAR168.
  2. Determine the recommended Phase 2 dose of C-CAR168 in subjects with autoimmune disease refractory to standard treatment.

Participants will be asked to:

  • Undergo screening to determine eligibility based on entry criteria.
  • Taper steroid use before leukapheresis.
  • Undergo leukapheresis for the manufacturing of C-CAR168.
  • Temporarily discontinue immunosuppressive therapy at least 7 days prior to leukapheresis.
  • Receive bridging therapy (steroids) if necessary to maintain disease stability during C-CAR168 manufacturing.
  • Undergo lymphodepletion therapy with fludarabine and cyclophosphamide.
  • Receive a single intravenous infusion of C-CAR168 at the assigned dose level on Day 0.
  • Attend regular safety and efficacy assessments for up to 24 months post-infusion.
  • Undergo dose-limiting toxicity evaluation during the first 28 days post-infusion (for those in the dose escalation phase).
  • Follow withdrawal procedures if necessary, including a discharge visit within 14 days if their condition deteriorates, unacceptable toxicity occurs, they no longer meet criteria, or they choose to withdraw.
03

Conditions studied

  • Lupus Nephritis (LN)

Keywords

  • Autoimmune
  • Lupus Nepritis
  • Systemic Lupus Erythematosus
  • CAR-T
  • CD20
  • C-CAR168
  • BCMA
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : Voluntary signed consent required.
  2. Age \& Gender: Males and females, 18-70 years old.
  3. Diagnosis: Clinical diagnosis of SLE per EULAR/ACR criteria for at least 6 months.
  4. Lupus Nephritis (LN): -confirmed active proliferative LN (Class III/IV ± V) within the past 12 months.
  5. Disease:

    • Treated with at least two for ≥8 weeks.
    • Stable but active disease despite standard therapy (, IS, monoclonal antibodies).
    • Steroid dose ≤30 mg/day (if applicable).
  6. Disease Activity at Screening:

    • SLE without LN: SLEDAI-2K ≥8 and 1 BILAG A or 2 BILAG B scores.
    • LN Patients: Proteinuria ≥1.0 g/day or UPCR ≥1.0 g/g.
  7. Autoantibody Status:

    o Positive ANA (≥1:80), anti-dsDNA (≥30 IU/mL), and/or anti-Smith antibody.

  8. Infection Status: No active infection within 2 weeks before leukapheresis.
  9. : Greater than 6 months.
  10. Adequate Organ Function:

    • Bone Marrow: ≥1.0×10⁹/L, ALC ≥0.5×10⁹/L, ≥80 g/L, ≥75×10⁹/L.
    • Coagulation: /APTT ≤1.5×.
    • Cardiac: ≥45% by ECHO/MUGA.
    • Pulmonary: SpO₂ ≥92% on room air.
    • Liver: /AST ≤2.5×ULN, total \<2.0 mg/dL.
    • Renal: ≥40 mL/min (Cockcroft-Gault).
  11. Pregnancy \& :

    • Women of must have a negative pregnancy test at screening.
    • Both male and female participants must use highly effective contraception for 1 year post-treatment.

Exclusion criteria

Exclusion Criteria:

  1. Any other concomitant diseases requiring long term systemic (oral or intravenously) treatment that may confound the interpretation of study results or have interference with background steroid tapering for the subjects.
  2. Any of the following:

    • Positive for surface antigen (HBsAg)/core antibody (HBcAb)/e antibody (HBeAb)/e antigen (HBeAg).
    • Positive for Virus (HCV) antibodies.
    • Positive for (HIV) antibodies.
    • Positive for syphilis antigen or antibody.
  3. Have an uncontrolled active infection.
  4. History of major organ transplantation (such as heart, lung, liver, kidney) or history of bone marrow/hematopoietic stem cell transplantation.
  5. History of any of stroke, unstable angina, myocardial infarction, congestive heart failure ( Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening.
  6. History of ≥ Grade 2 bleeding within the past 30 days.
  7. Received a within 4 weeks prior to signing the ICF.
  8. Received any of the following treatments:

    • Prednisone treatment of ≥ 100 mg/d or equivalent corticosteroid therapy for ≥14 days within the previous 8 weeks.
    • Receive plasma exchange, plasma separation, hemodialysis, or intravenous injection of immunoglobulin (IVIG) within 14 days prior to leukapheresis.
    • Use of any other clinical study drug within 28 days prior to leukapheresis. However, if the subject is not responsive to the treatment or have progressed and at least 3 half-lives have passed before the leukapheresis, he/she could be enrolled.
    • Previously received any CAR-T cell products or other genetically modified T cell therapies.
    • Rituximab/ocrelizumab/obinutuzumab within 6 months prior to screening
  9. Pregnant or breastfeeding women.
  10. History of seizure disorder, cerebrovascular ischemia/hemorrhage, dementia or cerebellar disease or other severe neuropsychiatric syndromes.
  11. History of deep vein thrombosis or pulmonary embolism within six months of infusion (line associated DVT is allowed)
  12. Diagnosed with malignant tumors within 5 years prior to signing the ICF, with the following exceptions: non-melanoma skin cancer that has been treated with radical therapy, localized prostate cancer, -confirmed cervical carcinoma in situ or squamous intraepithelial lesions detected by cervical smear, and completely excised breast carcinoma in situ.
  13. Poor compliance, unwilling or unable to adhere to the study protocol based on the investigator's assessment.
  14. Allergies to fludarabine, cyclophosphamide and/or known allergies to of C-CAR168 cell product.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 2: Dose Level 1 (DL1)

    Dose: 0.75 × 10⁶ CAR+ cells/kg Starting dose for escalation phase. First 3 subjects must be staggered by 28 days.

    Biological: C-CAR168

  • Experimental
    Arm 3: Dose Level 2 (DL2)

    Dose: 1.5 × 10⁶ CAR+ cells/kg Second dose level in escalation phase. Subject enrollment staggered by 28 days.

    Biological: C-CAR168

  • Experimental
    Arm 1: Dose Level -1 (DL-1)

    0.5 × 10⁶ CAR+ cells/kg Optional dose level, administered only upon Safety Review Committee (SRC) recommendation.

    Biological: C-CAR168

  • Experimental
    Arm 4: Dose Level 3 (DL3)

    Dose: 2.0 × 10⁶ CAR+ cells/kg Optional dose level pending SRC review and approval.

    Biological: C-CAR168

  • Experimental
    Arm 5: Dose Expansion Cohort

    Dose: To be selected based on MTD/RD identified in escalation phase. 12-24 additional subjects will be treated at the selected dose level. No staggered dosing required.

    Biological: C-CAR168

Interventions

  • BiologicalC-CAR168

    This is a multi-center, Phase 1/2, open-label, dose-escalation and dose-expansion study evaluating C-CAR168 for the treatment of autoimmune diseases refractory to standard therapy. A traditional 3+3 design is used to identify the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) in disease-specific cohorts.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events or Dose Limiting Toxicities

    The number and severity of Adverse Events (AE) and Serious Adverse Events (SAE), including dose limiting toxicities (DLTs) will be recorded.

    Time frame: Up to 24 months

Secondary outcomes

  1. To evaluate the efficacy of C-CAR168

    Proportion of subjects meeting the KDIGO 2024 Clinical Practice Guidelines' Definition of Remission, which includes complete response, primary efficacy renal response, or partial response.

    Time frame: Up to 24 months

  2. To evaluate the efficacy of C-CAR168

    Proportion of subjects achieving SLEDAI-2K response over time.

    Time frame: Up to 24 months

  3. To evaluate the efficacy of C-CAR168

    Proportion of subjects achieving British Isles Lupus Assessment Group (BILAG)(BILAG) response over time.

    Time frame: Up to 24 months

  4. Renal Related Events

    Record any renal related events during the study, including disease flare and the time to the event.

    Time frame: Up to 24 months

  5. Time to Response

    The number of days to response from the infusion of C-CAR0168 to the first recorded remission.

    Time frame: Up to 24 months

  6. Corticosteroid use

    The number of patients who achieved a low dose of steroids or no longer require.

    Time frame: Up to 24 months

  7. To characterize the cellular kinetics of C-CAR168

    Level of C-CAR168 positive cells in the blood.

    Time frame: Up to 24 months

  8. To assess immunogenicity of C-CAR168

    Presence of C-CAR168 antibodies.

    Time frame: Up to 24 months

  9. To evaluate the efficacy of C-CAR168

    Proportion of subjects whose for Physician Global Assessment (PGA) score does not worsen over time.

    Time frame: Up to 24 months

  10. To evaluate the efficacy of C-CAR168

    Proportion of subjects achieving a predefined score on the Visual Analog Scale (VAS) at specified time points. Efficacy will be assessed by evaluating changes in pain intensity as perceived by subjects, using the Visual Analog Scale (VAS). Subjects will rate their pain intensity on a scale from 0 (no pain) to 10 (worst imaginable pain). This will provide a subjective measure of pain severity over the course of the study.

    Time frame: Up to 24 months

  11. To assess changes for reported health-related quality of life, overall health status

    To assess changes from baseline for Functional Assessment of Chronic Illness Therapy (FACIT). The 13-item questionnaire will measure the level of fatigue and its impact on daily functioning. Higher scores reflect less fatigue and better overall energy levels.

    Time frame: Up to 24 months

  12. To assess changes for reported health-related quality of life, overall health status

    To assess changes from baseline for SF-36 (Short Form Health Survey). Efficacy will be assessed by evaluating changes in quality of life using the SF-36. Higher scores indicate better overall health and quality of life.

    Time frame: Up to 24 months

07

Study locations

1 site
  • AbelZeta, Inc.
    Rockville, Maryland 20850, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for May 2029, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 20, 2025
StartEst.
Jul 2026
Primary completionEst.
May 2029
CompletionEst.
Jun 2030
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06935474
Lead sponsor
AbelZeta Inc.
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
Jul 2026 (estimated)
Primary completion
May 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jul 16, 2026

Study contacts

Scott Antonia
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion